重庆智翔金泰生物制药股份有限公司 独立董事 2024 年度述职报告 作为重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"或"公司"） 董事会的独立董事，本人严格按照《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司独立董事管理办法》等相关法律法规和规章制度的规定及《重 庆智翔金泰生物制药股份有限公司章程》（以下简称《公司章程》）《独立董事工 作制度》的要求，严格遵循客观、公正、独立的履职原则，依托专业能力审慎行 使独董职权，通过全程参与董事会及股东大会，在重大决策中发表意见，切实维 护公司整体利益与中小投资者权益，忠实履行勤勉义务，为完善公司治理作出专 业贡献。 报告期内，公司第一届董事会于 2024 年 12 月 24 日完成换届选举，本人继 续担任公司第二届董事会独立董事，并履行董事会专门委员会相关职务。 现将本人 2024 年度的履职情况报告如下： 一、独立董事基本情况 （一）个人工作履历、专业背景及兼职情况 胡耘通先生，1982 年 11 月出生，中国国籍，无境外居留权，中国注册会计 师、法学博士、教授。2011 年 6 月至今，任西南政法大学教授；2011 年 11 月至 今，任重庆 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥20,155,818.67, a significant increase compared to the previous year's revenue of ¥6,330.27[4] - The net profit attributable to shareholders was -¥120,722,370.11, an improvement from -¥163,770,017.01 in the same period last year[4] - The net cash flow from operating activities was -¥110,686,349.98, compared to -¥144,561,278.97 in the previous year, indicating a reduction in cash outflow[4] - The weighted average return on net assets was -5.85%, showing a slight improvement from -6.04% in the previous year[4] - The net loss for Q1 2025 was ¥120,722,370.11, an improvement compared to a net loss of ¥163,770,017.01 in Q1 2024[20] - Basic and diluted earnings per share for Q1 2025 were both -¥0.33, compared to -¥0.45 in Q1 2024[20] Research and Development - Research and development expenses totaled ¥102,720,212.86, representing 509.63% of the operating revenue, reflecting a strong commitment to innovation[5] - The company continues to focus on expanding its product offerings and enhancing its market presence through ongoing research and development efforts[5] - The company has made progress in multiple research projects, with the approval of GR1501 for ankylosing spondylitis expected in January 2025[12] - The new drug application for GR1801 was accepted by the National Medical Products Administration (NMPA) in January 2025, indicating ongoing product development[12] - The company initiated Phase III clinical trials for GR1802 for chronic spontaneous urticaria in February 2025, showcasing its commitment to advancing its product pipeline[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,090,298,999.64, a decrease of 1.76% from the previous year's total assets of ¥3,145,716,912.53[5] - The total assets decreased from ¥3,145,716,912.53 to ¥3,090,298,999.64[17] - Total liabilities increased from ¥1,019,674,124.99 to ¥1,089,672,459.36[17] - The owner's equity attributable to the parent company decreased from ¥2,126,042,787.54 to ¥2,000,626,540.28[17] Cash Flow - As of March 31, 2025, the company's cash and cash equivalents amounted to ¥1,691,163,876.90, a decrease from ¥2,035,452,759.61 on December 31, 2024, representing a decline of approximately 17%[15] - The company's total current assets as of March 31, 2025, were ¥2,577,321,842.11, slightly down from ¥2,622,157,525.64 at the end of 2024, indicating a decrease of about 1.7%[15] - The company reported an increase in trading financial assets to ¥711,494,583.33 as of March 31, 2025, compared to ¥412,583,750.00 at the end of 2024, reflecting a growth of approximately 72%[15] - The accounts receivable rose to ¥15,004,941.09 from ¥12,007,485.25, marking an increase of about 25%[15] - The total cash outflow from operating activities was 160,623,910.13 RMB in Q1 2025, slightly higher than 158,287,926.91 RMB in Q1 2024[22] - The company received 30,314,468.83 RMB in other cash related to operating activities in Q1 2025, compared to 13,726,647.94 RMB in Q1 2024[22] - The company paid 79,098,052.94 RMB to employees in Q1 2025, an increase from 57,285,349.85 RMB in Q1 2024[22] - The cash outflow for taxes in Q1 2025 was 3,318,639.41 RMB, compared to 1,289,303.93 RMB in Q1 2024[22] - The company’s total cash inflow from operating activities was 49,937,560.15 RMB in Q1 2025, compared to 13,726,647.94 RMB in Q1 2024[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,205, indicating a stable shareholder base[8] - The top ten shareholders include significant institutional investors, with China Construction Bank holding 5,000,000 shares, representing 1.36% of total shares[11] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[11]

Financial Performance - The company reported product sales revenue of CNY 30.07 million as of December 31, 2024, marking its entry into the commercialization phase of innovative drugs [3]. - The company's revenue for 2024 reached ¥30,094,960.64, a significant increase of 2,384.10% compared to ¥1,211,502.42 in 2023, primarily due to the commercialization of the monoclonal antibody injection (金立希®) [24]. - The net loss attributable to shareholders for 2024 was ¥797,273,629.92, a slight improvement from a loss of ¥801,319,298.24 in 2023 [24]. - The net cash flow from operating activities for 2024 was -¥575,436,992.24, which increased from -¥377,580,702.25 in 2023, reflecting expanded operations and increased personnel costs [24]. - The basic earnings per share for 2024 was -¥2.17, compared to -¥2.50 in 2023, indicating a narrowing of losses [25]. - The company's total assets decreased by 12.49% to ¥3,145,716,912.53 at the end of 2024, down from ¥3,594,596,738.24 in 2023 [24]. - Financial expenses decreased compared to the previous year, contributing to the narrowing of net losses [24]. - The company reported a cash flow from operating activities of -152,925,921.04 RMB in Q4, indicating ongoing financial challenges [28]. - The company achieved sales revenue of 30,069,600 RMB from the newly launched drug, Saliqi monoclonal antibody injection, benefiting nearly 10,000 psoriasis patients [36]. Research and Development - Research and development expenses for the reporting period amounted to CNY 609.79 million, with a cumulative investment of CNY 1.68 billion over the past three years [4]. - The company plans to maintain high levels of R&D investment as several products enter critical registration clinical stages [4]. - The research and development expenditure as a percentage of revenue was exceptionally high at 2,026.23% for 2024, reflecting significant investment in new product development [26]. - The company is focused on accelerating product research and development to meet unmet clinical needs in the pharmaceutical sector [34]. - The company has established a dual-specific antibody discovery technology platform, enhancing its competitive edge in drug development [43]. - The company has 14 products in the pipeline, with 2 indications of the monoclonal antibody GR1501 approved for market, and GR1802's NDA accepted [47]. - The company has made significant progress in product development and commercialization in response to ongoing reforms in the pharmaceutical industry [34]. - The company has established a comprehensive system for R&D, procurement, production, and quality control [62]. - The company has established multiple quality research and analysis platforms to meet the quality control requirements of innovative biopharmaceuticals [69]. Commercialization Efforts - The company is focusing on advancing multiple projects in clinical research and has established a commercial sales team [4]. - The company plans to continue expanding its commercialization efforts following the approval of its new product, which has already started generating sales revenue [24]. - The company has established a commercialization team of nearly 200 people to enhance the marketing system for autoimmune disease products [36]. - The company signed strategic cooperation agreements with several well-known domestic distributors to enhance drug accessibility and overall sales effectiveness [36]. - The company is actively expanding its commercialization process and accelerating the construction of industrialization bases [47]. - The company is focused on increasing its operational scale and enhancing its workforce to support ongoing research and development initiatives [24]. Market and Industry Outlook - The biopharmaceutical market in China is expected to reach CNY 131.98 billion by 2030, with a compound annual growth rate (CAGR) of 14.4% from 2018 to 2030 [73]. - The global biopharmaceutical market is projected to reach USD 665.1 billion by 2030, with a CAGR of 8.1% from 2018 to 2030 [73]. - The increasing prevalence of cancer and autoimmune diseases is driving the demand for biopharmaceuticals in China, supported by improved healthcare awareness and diagnostic technologies [73]. - The penetration rate of innovative targeted biopharmaceuticals in clinical treatments is expected to continue rising, offering significant market potential [73]. - The biopharmaceutical industry is characterized by long R&D cycles and high risks, which may lead to further short-term losses for the company [5]. Governance and Management - The company has a stable core management and R&D team, with good cash reserves [4]. - The company emphasizes talent development and strategic reserve, enhancing its innovation capabilities through a comprehensive talent ecosystem [39]. - The company is committed to improving its governance structure and internal management efficiency to comply with relevant laws and regulations [164]. - The company has established a comprehensive compensation policy that includes basic salary, performance bonuses, and various benefits [190]. - The company has a performance-based salary adjustment mechanism to align individual performance with company results [190]. Risks and Challenges - The company has not yet achieved profitability and has accumulated losses due to high investment in drug development and commercialization processes [3]. - The company emphasizes the importance of monitoring investment risks due to potential adverse impacts on financial conditions from ongoing R&D expenditures [5]. - The company is facing risks related to market competition, drug pricing policies, and potential loss of core technical personnel, which could adversely affect its business operations [105][106][111]. - The company's commercialization efforts are still in the early stages, which may lead to uncertainties in profitability if results do not meet expectations [102].

重庆智翔金泰生物制药股份有限公司 2024 年度 募集资金年度存放与使用情况鉴证报告 | 蒙引 | 页码 | | --- | --- | | 鉴证报告 | 1-2 | | 关于募集资金 2024 年度存放与使用情况的专项报告 | 1-7 | . 联系电话: +86(010) 6554 2288 北京市东城区朝阳门北大街 信永中和会计师事务所 telephone: +86 (010) 6554 2288 8 号富华大厦 A 座 9 层 9/F. Block A. Fu Hua Mansion No.8, Chaoyangmen Beidajie ShineWir Donachena District, Beijing 100027. P.R.China certified public accountants 募集资金年度存放与使用情况鉴证报告 XYZH/2025BJAA11B0115 重庆智翔金泰生物制药股份有限公司 重庆智翔金泰生物制药股份有限公司全体股东: 我们对后附的重庆智翔金泰生物制药股份有限公司(以下简称智翔金泰公司) 募集 资金年度存放与使用情况专项报告执行了鉴证工作。 智翔金泰公司管理层的责任是 ...

●重庆智翔金泰生物制药股份有限公司（以下简称"公司"）拟使用额度不 超过人民币 50,000 万元（含本数）的闲置募集资金临时补充流动资金，用于与 公司主营业务相关的生产经营。 ●使用期限自公司董事会审议通过之日起不超过 12 个月 证券代码：688443 证券简称：智翔金泰 公告编号：2025-016 重庆智翔金泰生物制药股份有限公司 关于使用部分闲置募集资金临时补充流动资金公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2025 年 4 月 25 日召开第二届董事会第二次会议、第二届监事会第二 次会议，审议通过了《关于使用部分闲置募集资金临时补充流动资金的议案》， 根据公司募集资金投资项目的资金使用计划及项目的建设进度，公司在确保不影 响募集资金投资项目建设进度，不改变募集资金用途，不影响募集资金投资计划 正常进行的前提下，为了提高募集资金使用效率、降低公司财务成本、解决公司 运营发展的资金需求，董事会同意公司以部分闲置募集资金临时补充流动资金。 现将相关事项公告如下： 一、募集资金基本情况 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2025-013 重庆智翔金泰生物制药股份有限公司 关于公司 2025 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东大会审议：否 日常关联交易对上市公司的影响：重庆智翔金泰生物制药股份有限公司 （以下简称"公司"）预计的2025年度日常关联交易，是基于公司和关联方之间的 正常生产经营需要。关联交易遵循公平合理的定价原则，不存在损害公司及股东 利益的情形，不影响公司的独立性，不会对关联方形成依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于 2025 年 4 月 15 日召开第二届董事会审计委员会第三次会议，通过了 《关于公司 2025 年度日常关联交易预计的议案》，并同意该议案提交至公司董事 会审议。 公司于2025年4月25日召开第二届董事会第二次会议、第二届监事会第二次会 议，审议通过了《关于公司2025年度日常关联交易预计的议案》。关联董事蒋仁生 回避了相关事项的表决，出席会议 ...

重庆智翔金泰生物制药股份有限公司 2024 年度"提质增效重回报"行动方案评估报告 及 2025 年度行动方案 为积极响应上海证券交易所关于开展科创板上市公司"提质增效重回报"专项 行动的倡议，践行"以投资者为本"的发展理念，持续推动企业高质量发展，积极 承担上市公司责任，提升投资价值，重庆智翔金泰生物制药股份有限公司（以下简 称"公司"）于 2024 年 7 月 16 日发布了《重庆智翔金泰生物制药股份有限公司 2024 年度"提质增效重回报"行动方案》。为进一步提高公司质量、提升公司投资价值， 结合公司 2024 年度行动方案执行情况，公司制定了《重庆智翔金泰生物制药股份 有限公司 2024 年度"提质增效重回报"行动方案评估报告及 2025 年度行动方案》。 该方案于 2025 年 4 月 25 日经公司第二届董事会第二次会议审议通过，现将相关方 案报告如下： 一、聚焦主营业务，创新驱动，持续加大研发投入 公司是一家创新驱动型生物制药企业，主营业务为抗体药物的研发、生产与销 售，公司在研产品为单克隆抗体药物和双特异性抗体药物。 公司在源头创新方面建立了基于新型噬菌体呈现系统的单抗药物发现技术平 台和双特 ...

关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等法律法规及重庆智翔金泰生物制药股份有限公 司(以下简称"公司")《重庆智翔金泰生物制药股份有限公司章程》《独立董事 工作制度》的规定，公司董事会就公司在任独立董事崔萱林、陈利、胡耘通的独 立性情况进行评估并出具如下专项意见： 经核查独立董事崔萱林、陈利、胡耘通及其直系亲属和主要社会关系人员的 任职经历以及独立董事签署的相关自查文件，独立董事崔萱林、陈利、胡耘通不 存在《上市公司独立董事管理办法》第六条不得担任独立董事的情形，在担任公 司独立董事期间，严格遵守中国证监会和上海证券交易所的相关规定，确保有足 够的时间和精力勤勉尽责地履行职责，作出独立判断，不受公司主要股东、实际 控制人或其他与公司存在利害关系的单位或个人的影响。公司独立董事崔萱林、 陈利、胡耘通符合《上市公司独立董事管理办法》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》等相关法律法规以及《重庆智翔金泰生 物制药股份有限公司章程》《独立董事工作制度》等内部制度中对独立董事独立 性的相关要求。 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2025-019 重庆智翔金泰生物制药股份有限公司 关于部分募投项目新增子项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 重庆智翔金泰生物制药股份有限公司（以下简称"公司"）拟对首次公开 发行股票募投项目中"抗体药物研发项目"的部分子项目拓展适应症。 本次"抗体药物研发项目"部分子项目拓展适应症是公司综合考虑市场、 行业环境的变化，基于公司经营发展战略需要做出的审慎决定，未改变募投项目 实施主体，未改变募投项目的性质和投资目的，不会对公司的正常经营产生影响， 也不存在损害公司及全体股东利益的情形。 本事项尚需提交公司股东大会审议。 公司于 2025 年 4 月 25 日召开了公司第二届董事会第二次会议、第二届监事 会第二次会议，审议通过了《关于部分募投项目新增子项目的议案》，同意公司 对首次公开发行股票募投项目中"抗体药物研发项目"部分子项目进行适应症拓 展。 公司独立董事专门会议已审议通过上述事项，该事项尚需提交公司股东大会 审议。保荐机构 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2025-018 重庆智翔金泰生物制药股份有限公司 关于续聘公司 2025 年度审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：信永中和会计师事务所（特殊普通合伙）（以 下简称"信永中和"） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 名称：信永中和会计师事务所（特殊普通合伙） 成立日期：2012 年 3 月 2 日 组织形式：特殊普通合伙企业 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 首席合伙人：谭小青先生 截止 2024 年 12 月 31 日，信永中和合伙人（股东）259 人，注册会计师 1780 人。签署过证券服务业务审计报告的注册会计师人数超过 700 人。 信永中和 2023 年度业务收入为 40.46 亿元，其中，审计业务收入为 30.15 亿 元，证券业务收入为 9.96 亿元。2023 年度，信永中和上市公司年报审计项目 364 家，收费总额 4.5 ...